trending Market Intelligence /marketintelligence/en/news-insights/trending/cIg5S0Hpcgtlt-18Olh2wQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA tightens requirements for Bayer's post-market study of Essure device

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA tightens requirements for Bayer's post-market study of Essure device

The U.S. Food and Drug Administration has tightened the standards for Bayer AG's post-market study of the permanent birth control medical device Essure, which has come under scrutiny by the agency for causing severe side effects in some women.

The FDA made three major changes to what they call a post-market surveillance study, which is when the agency requires companies to continue studying medical device products even though they have been approved or cleared to be sold.

Bayer will now be required to conduct additional blood testing of patients enrolled in the study during follow-up visits so the agency can evaluate immune reaction to the device. The company will have to continue to enroll patients in the study for five years, rather than three. Bayer will also enroll women in the study who opt to have the device implanted before the product is removed from shelves as planned.

The post-market study was first required by the agency in 2016. But Essure was brought back into the spotlight by the 2018 documentary The Bleeding Edge. The documentary profiled women who have experienced serious risks and complications from the device years after insertion.

Essure, which was approved by the FDA in 2002, is the only contraceptive implant that does not require a surgical incision. The device is a metal coil that when placed into the fallopian tubes prevents pregnancy, and is designed as an alternative to tubal ligation.

Patients who have received the device have reported serious health risks such as persistent pain, bleeding of the uterus, and movement of the device's coils into the pelvis or abdomen.

The device is scheduled to go off the U.S. market on Dec. 31, 2018, but FDA Commissioner Scott Gottlieb said Dec. 20 that the agency's oversight of the device will continue. Since 2016, sales of Essure declined by 70%, according to the agency.

Along with the post-market study, the FDA has required Bayer to place a warning label and patient decision checklist on the box for the product advising users of potential risks. The FDA in April also required healthcare providers and facilities to provide women with information regarding the health risks of the device prior to its sale or distribution.

Bayer has defended the safety of the product and said that Essure was being pulled from the U.S. market because of the drop in sales. In a Dec. 20 press release about the FDA's changes to the post-market study, the company reaffirmed its position that the device is safe for use.

"Bayer has worked cooperatively with the FDA throughout the implementation of the study and on these study amendments, which provide a measure of flexibility for patient enrollment and allow us to collect additional and valuable long-term data," said Edio Zampaglione, vice president of U.S. medical affairs, women's healthcare and neurology at Bayer.